Updates in ALK-Positive Non–Small Cell Lung Cancer

On May 4, 2021, a select group of oncologists participated in a virtual workshop to discuss the treatment landscape and management of patients with ALK-positive NSCLC. This article summarizes key data about ALK-positive NSCLC as well as insights from stakeholder discussions regarding this topic.

Related Videos
Brian Mitzman, MD, FACS, FCCP
Maya Khalil, MD, assistant professor of medicine, Division of Hematology and Oncology, the University of Alabama at Birmingham (UAB), oncologist, O’Neal Comprehensive Cancer Center, UAB Medicine
Julie Renee Brahmer, MD
Brian Mitzman, MD, FACS, FCCP
Anne Chiang, MD, PhD, associate professor, medical oncology, Yale School of Medicine, associate cancer center director, Clinical Initiatives, Smilow Cancer Hospital, Yale Cancer Center
Brian Henick, MD
Amy L. Cummings, MD, thoracic oncologist, assistant professor of medicine, David Geffen School of Medicine, University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center
Timothy Burns, MD, PhD, associate professor of medicine, associate program director, Research, associate program director, Hematology/Oncology Fellowship Program, Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center
Brian Henick, MD
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Related Content

Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC

April 1st 2023

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC

March 31st 2023

FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC

March 9th 2023

Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC

March 30th 2023

Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC

March 30th 2023

Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC

April 1st 2023

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC

March 31st 2023

FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC

March 9th 2023

Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC

March 30th 2023

Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC

March 30th 2023

Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC

April 1st 2023

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC

March 31st 2023

FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC

March 9th 2023

Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC

March 30th 2023

Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC

March 30th 2023